Yaribeygi Habib, Mohammadi Mohammad Taghi, Sahebkar Amirhossein
Health Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Chronic Kidney Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Drug Res (Stuttg). 2018 Jun;68(6):355-360. doi: 10.1055/s-0043-121143. Epub 2018 Feb 12.
Diabetes-induced oxidative stress has an essential role in pancreatic cells dysfunction. The present study aimed to evaluate whether peroxisome proliferator activated receptor- alpha (PPAR-α) induction by fenofibrate counterbalances oxidative stress in pancreatic cells.
In this in vivo study, male Wistar rats were randomly divided into four groups as normal, normal treated, diabetic and diabetic treated groups (n=6 in each group). Diabetes was induced by a single intravenous injection of streptozotocin (45 mg/kg). Treated animals received fenofibrate for 8 weeks (80 mg/kg/day) orally. At the end of the 8 week, rats were sacrificed and blood samples and pancreas tissues were collected. Then, the content of malondialdehyde (MDA), nitrate (Nox) and glutathione (GLT) and enzymatic activities of catalase (CAT) and superoxide dismutase (SOD) were assessed. D ata were analyzed using two-way ANOVA.
Diabetes deteriorated anti-oxidant defense capacity in pancreatic cells by reducing SOD and CAT activities and induced oxidative stress as reflected by increased MDA content and free radicals production (Nox content). Treatment by fenofibrate increased SOD and CAT activities and improved oxidative stress by decreasing pancreatic MDA and Nox levels.
Uncontrolled hyperglycemia weakens anti-oxidant defense capacity in pancreatic cells and contributes to oxidative stress. PPAR-α induction by fenofibrate can restore anti-oxidant defense systems and improve diabetes-induced oxidative stress.
糖尿病诱导的氧化应激在胰腺细胞功能障碍中起重要作用。本研究旨在评估非诺贝特诱导过氧化物酶体增殖物激活受体-α(PPAR-α)是否能抵消胰腺细胞中的氧化应激。
在这项体内研究中,雄性Wistar大鼠被随机分为四组,即正常组、正常治疗组、糖尿病组和糖尿病治疗组(每组n = 6)。通过单次静脉注射链脲佐菌素(45 mg/kg)诱导糖尿病。治疗组动物口服非诺贝特8周(80 mg/kg/天)。在8周结束时,处死大鼠并采集血样和胰腺组织。然后,评估丙二醛(MDA)、硝酸盐(Nox)和谷胱甘肽(GLT)的含量以及过氧化氢酶(CAT)和超氧化物歧化酶(SOD)的酶活性。数据采用双向方差分析进行分析。
糖尿病通过降低SOD和CAT活性损害了胰腺细胞的抗氧化防御能力,并通过增加MDA含量和自由基产生(Nox含量)诱导了氧化应激。非诺贝特治疗增加了SOD和CAT活性,并通过降低胰腺MDA和Nox水平改善了氧化应激。
不受控制的高血糖会削弱胰腺细胞的抗氧化防御能力并导致氧化应激。非诺贝特诱导PPAR-α可恢复抗氧化防御系统并改善糖尿病诱导的氧化应激。